---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090744"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T12:58:35.723975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range

## Summary
- Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.
- Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.
- Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).
- FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.
- Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024.

## SEC filing metadata
- accession: 0000950170-24-090744
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/0000950170-24-090744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/rxst-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090744
- JSON: https://secwatch.observer/filing/0000950170-24-090744.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.